Current Opinion in Oncology

Article	Citations
Epidemiology of head and neck cancers: an update	155
Lung cancer in China: current and prospect	131
Molecular alterations in meningioma: prognostic and therapeutic perspectives	51
Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting	49
Advances in immunotherapy for cervical cancer	47
The microenvironment in myeloma	42
Update on oncogenesis and therapy for Kaposi sarcoma	37
Models of supportive care in oncology	35
Viral strategies for circumventing p53: the case of severe acute respiratory syndrome coronavirus	31
Use of noninvasive imaging in the management of skin cancer	31
Computational analysis of flow cytometry data in hematological malignancies: future clinical practice?	31
BRAF mutations in thyroid cancer	27
Malignant pleural mesothelioma: recent developments	26
Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma	24
Recent progress in treating advanced prostate cancer	24
CD19-directed CAR T-cell therapy in B-cell NHL	23
Antibody–drug conjugates in breast cancer: the chemotherapy of the future?	23
Current concepts in the treatment of giant cell tumour of bone	22
Targeting HER2 heterogeneity in early-stage breast cancer	20
Single-cell and spatial transcriptomics approaches of the bone marrow microenvironment	18
Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives	17
Filling the gaps of patient information and comprehension	17
Multimodality treatment for localized gastric cancer: state of the art and new insights	17
Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer	16
Current emerging MRI tools for radionecrosis and pseudoprogression diagnosis	16

Molecular prediction of metastasis in cutaneous squamous cell carcinoma	16
Targeting SUMOylation in cancer	16
Sinonasal cancers treatments: state of the art	16
The roaring 2020s: a new decade of systemic therapy for renal cell carcinoma	16
Geriatric assessments and frailty scores in multiple myeloma patients: a needed tool for individualized treatment?	15
Single-cell sequencing in hematology	15
MEK inhibitors in RASopathies	15
Mechanisms of invasion in glioblastoma	14
New drugs in gastrointestinal stromal tumors	14
Cabozantinib as an emerging treatment for sarcoma	14
T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities	14
Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma	14
Adrenocortical carcinoma: current treatment options	13
Updated concepts in treatment of giant cell tumor of bone	13
Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?	13
The role of the tumor matrix environment in progression of head and neck cancer	13
Retroperitoneal sarcoma: the Transatlantic Australasian Retroperitoneal Sarcoma Working Group Program	13
Adjuvant therapy of operable nonsmall cell lung cancer: an update	13
Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA pathway): data and perspectives	12
Targeted radionuclide therapy: an emerging field in solid tumours	12
Adjuvant chemotherapy in rectal cancer: state of the art and future perspectives	12
The emerging data on choice of optimal therapy for locally advanced nasopharyngeal carcinoma	12
New targets and technologies for CAR-T cells	12
Opportunities and challenges associated with the evaluation of chimeric antigen receptor T cells in real-life	12
The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together	12
Next-generation sequencing for the management of sarcomas with no known driver mutations	12
Immunotherapy and breast cancer: an overview	12
The role of myeloid-derived suppressor cells in hematologic malignancies	11
Therapeutic targeting of the DNA damage response in prostate cancer	11
Lifestyle and quality of life in patients with early-stage breast cancer receiving adjuvant endocrine therapy	11
EGFR-mutant NSCLC: emerging novel drugs	11
Challenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery	11
Dissecting the spatial bone marrow microenvironment of hematopoietic stem cells	11
Management of epilepsy in brain tumor patients	10
Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?	10
Immunobiology of Merkel cell carcinoma	10
Preoperative immunotherapy for head and neck cancers: state of art	10
Harnessing dendritic cells for innovative therapeutic cancer vaccines	10
Indications of next-generation sequencing in non-Hodgkin's lymphoma	9
Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment	9
Tropomyosin receptor kinase inhibitors in the management of sarcomas	9
Treatment updates on tenosynovial giant cell tumor	9
Bromodomain and extraterminal domain protein bromodomain inhibitor based cancer therapeutics	9
Systemic treatment of metastatic squamous cell carcinoma of the head and neck: proposal for management changes	9
Novel therapeutic options for alveolar soft part sarcoma: antiangiogenic therapy, immunotherapy and beyond	9
Adjuvant chemotherapy in colon cancer: state of the art and future perspectives	9
New perspectives on targeting RAF, MEK and ERK in melanoma	9
131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma	9
Novel immunotherapeutic drugs for the treatment of lung cancer	8
Interventions addressing fear of cancer recurrence: challenges and future perspectives	8

Combining immunotherapy and radiotherapy in head and neck squamous cell cancers: which perspectives?	8
Immunomodulation for hepatocellular carcinoma therapy: current challenges	8
Image-guided surgery in oral cancer: toward improved margin control	8
Immune escape mechanisms in head and neck squamous cell carcinoma and implication for new immunotherapy approach	8
Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting	8
An update on adult forms of hereditary pheochromocytomas and paragangliomas	8
New molecular entities of soft tissue and bone tumors	8
Mitogen-activating protein kinase pathway alterations in Langerhans cell histiocytosis	8
Primary vitreoretinal lymphoma: short review of the literature, results of a European survey and French guidelines of the LOC network for diagnosis, treatment and follow-up	8
Recent advances in primary resistance mechanisms against immune checkpoint inhibitors	8
Overcoming key challenges in cancer immunotherapy with engineered T cells	8
Is less more in the surgical treatment of early-stage cervical cancer?	8
Mechanisms of resistance and predictive biomarkers of response to targeted therapies and immunotherapies in metastatic melanoma	7
Role of metabolic imaging in diagnosis of primary, metastatic, and recurrent prostate cancer	7
Epigenetic focus on angioimmunoblastic T-cell lymphoma: pathogenesis and treatment	7
Lung cancer screening: a critical appraisal	7
Current status of phosphoinotiside-3 kinase inhibitors in blood cancers	7
Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives	7
COVID-19 and supportive cancer care: key issues and opportunities	7
Targeting microRNA in hematologic malignancies	7
Medical treatment of advanced malignant perivascular epithelioid cell tumors	7
Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia	7
Perspectives in pathomics in head and neck cancer	6
Desmoid tumors: who, when and how to treat?	6
HIPEC in advanced epithelial ovarian cancer: why is there controversy?	6
The road to chemotherapy-free treatment in chronic lymphocytic leukaemia	6
Tyrosine kinase inhibitors as induction therapy in nonsmall-cell lung cancer	6
Targeting the methionine−methionine adenosyl transferase 2A−S-adenosyl methionine axis for cancer therapy	6
Anaplastic thyroid carcinoma: advances in molecular profiling and targeted therapy	6
Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data	6
Supportive care for new cancer therapies	6
Bacterial infection-driven lymphomagenesis	6
Immunotherapy combinations in advanced nonsmall cell lung cancer	5
Adjuvant treatment of early male breast cancer	5
Emergency management of immune-related toxicity	5
How to treat lobular cancer in the adjuvant setting?	5
EBV-associated NK and T-cell lymphoid neoplasms	5
Embryonal tumors of the central nervous system	5
Use of staging for sex cord stromal tumours	5
A challenging frontier – the genomics and therapeutics of nonclear cell renal cell carcinoma	5
Prognostic factors in primary central nervous system lymphoma	5
Epigenetic in medullary thyroid cancer: the role of microRNA in tumorigenesis and prognosis	5
Immunotherapy in multiple myeloma: when, where, and for who?	5
Emerging systemic antitarget treatment for differentiated thyroid carcinoma	5
Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpoints	5
Can we cure oligometastatic disease? A practical point of view	5
Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer	5
Biomarkers and immunotherapy: where are we?	5
Transcriptional and epigenetic control of early life cell fate decisions	5
The multiple molecular dimensions of long noncoding RNAs that regulate gene expression and tumorigenesis	5
New imaging modalities to distinguish rare uterine mesenchymal cancers from benign uterine lesions	5
The role of autologous stem-cell transplantation in multiple myeloma in 2021	5
Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations	5
Advances in myelodysplastic syndrome	5
Mutational burden and immune recognition of gliomas	5
Hairy cell leukemia: a brief update on current knowledge and treatment prospects	4
The evolving treatment landscape of advanced urothelial carcinoma	4
Importance of guidelines and networking for the management of rare gynecological cancers	4
Tropomyosin receptor kinases in sarcomas – of joy and despair	4
Circulating tumour DNA dynamics for assessment of molecular residual disease and for intercepting resistance in breast cancer	4
New treatments in advanced gastrointestinal stromal tumor	4
Artificial intelligence: opportunities in lung cancer	4
Immunotherapy in gynecological cancers: where are we?	4
Desmoid-type fibromatosis: toward a holistic management	4
New developments in rare vulvar and vaginal cancers	4
Next questions for the medical treatment of gastrointestinal stromal tumor	4
CIC-DUX4 sarcomas	4
Ten steps to establish a national centre for gestational trophoblastic disease	4
Challenges adopting next-generation sequencing in community oncology practice	4
Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice	4
Emerging role of multiparametric magnetic resonance imaging in identifying clinically relevant localized prostate cancer	4
Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy	4
Neoadjuvant immunotherapy in nonsmall cell lung cancer	4
The changing landscape for patients with relapsed/refractory acute myeloid leukaemia	4
Fundamentals of liquid biopsies in metastatic prostate cancer: from characterization to stratification	4
Immunotherapy of sarcomas with modified T cells	4
The role of next-generation sequencing in acute myeloid leukemia	4
WHO 2021 and beyond: new types, molecular markers and tools for brain tumor classification	4
Immunotherapy in sarcoma: combinations or single agents? In whom?	4
Content features and its implementation in novel app-based psycho-oncological interventions for cancer survivors: a narrative review	4

Angiogenesis inhibition in lung cancer: emerging novel strategies	4
Multikinase inhibitors for the treatment of radioiodine refractory thyroid cancer: what have we learned from the ‘real-world’ experience?	4
Antibodies targeting Prostate-Specific Membrane Antigen positive prostate cancer: from diagnostic imaging to theranostics	4
Targeting defective DNA repair in prostate cancer	4
Understanding the tumor-immune microenvironment in prostate cancer	4
Prevention of brain metastases in human epidermal growth factor receptor 2-positive breast cancer	4
Thoracic irradiation as consolidation therapy in patients with extensive-stage small cell lung cancer	3
MAPK blockade, toxicities, pathogenesis and management	3
Educational needs of self-care in cachectic cancer patients and caregivers	3
Renal oncocytoma: a challenging diagnosis	3
Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia	3
Mitogen-activated protein kinase blockade in melanoma: intermittent versus continuous therapy, from preclinical to clinical data	3
Targeting cancer stem cell pathways for lung cancer therapy	3
Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer: is there a role?	3
Adjuvant and neoadjuvant approaches in pancreatic cancer	3
Editorial: Lung cancer: continuous progress in diagnosis and treatment	3
Maintenance therapies in acute myeloid leukemia: the renaissance of an old therapeutic concept	3
Ovarian preservation in gynecologic oncology: current indications and techniques	3
Oral microbiome as a new research-target for supportive care and precision oncology	3
Clinical management of brain tumors in pregnancy	3
Melanoma with genetic alterations beyond the BRAF V600 mutation: management and new insights	3
New horizons in early drugs development in solid cancers	3
Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results	3
Current treatments of medulloblastoma	3
Novel treatment approaches for HER2 positive solid tumors (excluding breast cancer)	3
Postneoadjuvant treatment for triple-negative breast cancer	3
Highlighting recent treatment advances in metastatic prostate cancer: expanding the treatment arsenal	3
Real world data regarding the management of cancer-associated thrombosis	3
A precision medicine approach to management of acute myeloid leukemia in older adults	3
Epstein-Barr virus-associated posttransplant lymphoproliferative disorders: new insights in pathogenesis, classification and treatment	3
Immunotherapy in rare ovarian cancer	3
Molecular genotyping of adrenocortical carcinoma: a systematic analysis of published literature 2019–2021	3
Novel next-generation sequencing-based methodologies to characterize the mutational consequences of (prenatal) chemotherapy exposure in noncancerous tissue	3
New perspectives in liquid biopsy for glioma patients	3
Systemic treatment of recurrent and/or metastatic squamous cell carcinomas of the head and neck: what is the best therapeutic sequence?	3
State of the art and future directions in the systemic treatment of medullary thyroid cancer	3
Surgical management of skull base meningiomas and vestibular schwannomas	3
What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma?	3
The path to personalized treatment in advanced and metastatic biliary tract cancers: a review of new targeted therapies and immunotherapy	3
Psycho-oncology interventions focusing on fatigue and sleep disturbances	3
How to support parenting in patients with cancer and co-parents? From research to practice	3
Nanoparticle therapy for head and neck cancers	3
Editorial: Supportive care: do we need a model?	3
State of the art and future directions in the systemic treatment of neuroendocrine neoplasms	3
Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions	3
Kirsten rat sarcoma inhibitors in clinical development against nonsmall cell lung cancer	3
Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers	3